Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to $197.6 million.

  • ImmunityBio's Short-term Investments rose 97370.25% to $197.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $197.6 million, marking a year-over-year increase of 97370.25%. This contributed to the annual value of $6.4 million for FY2024, which is 53240.83% up from last year.
  • Per ImmunityBio's latest filing, its Short-term Investments stood at $197.6 million for Q3 2025, which was up 97370.25% from $16.0 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Short-term Investments ranged from a high of $197.6 million in Q3 2025 and a low of $931000.0 during Q1 2025
  • Over the past 5 years, ImmunityBio's median Short-term Investments value was $16.0 million (recorded in 2025), while the average stood at $41.0 million.
  • As far as peak fluctuations go, ImmunityBio's Short-term Investments plummeted by 9821.29% in 2023, and later skyrocketed by 348966.5% in 2024.
  • Quarter analysis of 5 years shows ImmunityBio's Short-term Investments stood at $136.0 million in 2021, then plummeted by 98.13% to $2.5 million in 2022, then tumbled by 60.32% to $1.0 million in 2023, then soared by 532.41% to $6.4 million in 2024, then soared by 2996.25% to $197.6 million in 2025.
  • Its Short-term Investments stands at $197.6 million for Q3 2025, versus $16.0 million for Q2 2025 and $931000.0 for Q1 2025.